InfuSystem (NYSEAMERICAN:INFU) Stock Rating Upgraded by StockNews.com

InfuSystem (NYSEAMERICAN:INFU) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday.

InfuSystem Stock Performance

Shares of NYSEAMERICAN INFU opened at $7.81 on Wednesday. The stock has a market capitalization of $165.93 million, a price-to-earnings ratio of 260.25 and a beta of 1.24. The company has a quick ratio of 1.54, a current ratio of 1.95 and a debt-to-equity ratio of 0.56. InfuSystem has a 52 week low of $7.75 and a 52 week high of $11.44.

Institutional Trading of InfuSystem

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of InfuSystem by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 1,065,298 shares of the medical instruments supplier’s stock valued at $11,228,000 after acquiring an additional 23,976 shares during the last quarter. Meros Investment Management LP lifted its position in InfuSystem by 0.4% in the 4th quarter. Meros Investment Management LP now owns 884,090 shares of the medical instruments supplier’s stock worth $9,318,000 after buying an additional 3,709 shares during the last quarter. Barclays PLC lifted its position in InfuSystem by 552.0% in the 4th quarter. Barclays PLC now owns 25,638 shares of the medical instruments supplier’s stock worth $270,000 after buying an additional 21,706 shares during the last quarter. Nuveen Asset Management LLC lifted its position in InfuSystem by 14.5% in the 4th quarter. Nuveen Asset Management LLC now owns 73,931 shares of the medical instruments supplier’s stock worth $779,000 after buying an additional 9,354 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in InfuSystem by 9.9% in the 4th quarter. Royal Bank of Canada now owns 44,241 shares of the medical instruments supplier’s stock worth $467,000 after buying an additional 3,968 shares during the last quarter. Institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.